Metabolic active tumour volume quantified on [18F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients.

Ana Luísa Gomes RochaMauro Alessandro Monteiro da Conceição Francisco Xavier Proença da Cunha Sequeira Mano Helder Carvalho Martins Gracinda Maria Lopes Magalhães Costa Bárbara Cecília Bessa Dos Santos Oliveiros Paiva Paula Alexandra Amado Lapa

Published in: Journal of cancer research and clinical oncology (2021)

Baseline MTVWB, measured on staging [18F]FDG PET/CT, further stratifies stage IV NSCLC patients. This parameter is an independent predictor of OS and provides valuable prognostic information over the 8th edition of cTNM staging.

Keyphrases

end stage renal disease
lymph node
ejection fraction
newly diagnosed
pet ct
single cell
peritoneal dialysis
stem cells
healthcare
cell therapy
patient reported outcomes
bone marrow